Sanofi-Aventis has acquired Zentiva N.V.
Sanofi-Aventis has successfully completed and settled the voluntary tender offer for all of Zentiva N.V.'s shares. Total value of this transaction is over US$2 billion.
Sanofi-Aventis, a leading global pharmaceutical company, discovers, develops and distributes a broad offering of medicines, vaccines and integrated healthcare solutions adapted to local needs and means. Sanofi-Aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Zentiva N.V. is an international pharmaceutical company focused on developing, manufacturing and marketing modern generic pharmaceutical products. The company has leading positions in the pharmaceutical markets in the Czech Republic, Slovakia, Romania and Turkey, and is growing rapidly in Poland, Russia, Bulgaria, Hungary, the Ukraine and the Baltic States.
Oaklins' team in the Czech Republic acted as the tender agent to Sanofi-Aventis in relation to the voluntary tender offer for all of Zentiva N.V.'s shares. From July 2008 to March 2009, the Czech team arranged the purchase of approximately 70% of the issued share capital of Zentiva.
Contacter l'équipe de la transaction
Directeur généralPrague, République tchèque
Oaklins WOOD & Co.
Narva clinics has been acquired by Narva Åderbråckscenter AB
The founder and some key employees of Åderbråcksspecialisterna Narva Kirurg Center AB and Narva Derma Center AB (Narva) have completed an MBO.En apprendre plus
NS PARTNERS CO., LTD. has been acquired by JMDC Inc.
Noritsu Koki Co., Ltd has sold NS PARTNERS CO., LTD. to JMDC Inc.En apprendre plus
Protalix BioTherapeutics, Inc. has completed a private stock placement
Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.En apprendre plus